trans-4-methyl-2-hexenal | 80780-73-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-4-methyl-2-hexenal
• 英文别名: (E)-4-methyl-2-hexenal；4-Methylhex-2-enal；(E)-4-methylhex-2-enal
• CAS: 80780-73-0
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: PKOVRWKTLYBDGH-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  trans-4-methyl-2-hexenal 在 platinum on activated charcoal 草酰氯 、 氢气 、 二甲基亚砜 作用下， 以 乙醚 、 乙醇 为溶剂， 生成 2,8-dimethyldecan-5-one
  参考文献：
  名称：

  2,6,10-Trimethyl-7-(3-methylbutyl)-dodecane, a novel sedimentary biological marker compound.

  摘要：

  DOI：

  10.1016/s0040-4039(00)87283-4
• 作为产物：
  描述：

  2-甲基丁醇 在 lithium aluminium tetrahydride 、 草酰氯 、 sodium hydride 、 二甲基亚砜 作用下， 生成 trans-4-methyl-2-hexenal
  参考文献：
  名称：

  2,6,10-Trimethyl-7-(3-methylbutyl)-dodecane, a novel sedimentary biological marker compound.

  摘要：

  DOI：

  10.1016/s0040-4039(00)87283-4

文献信息

• NOVEL 9,10-BIS(1,3-DITHIOL-2-YLIDENE)-9,10-DIHYDROANTHRACENE POLYMERS AND USE THEREOF
  申请人：HAEUPLER Bernhard

  公开号：US20170179525A1

  公开（公告）日：2017-06-22

  The problem addressed was that of providing novel polymers which are preparable with a low level of complexity, with the possibility of controlled influence on the physicochemical properties thereof within wide limits in the course of synthesis, and which are usable as active media in electrical charge storage elements for high storage capacity, long lifetime and stable charging/discharging plateaus. 9,10-Bis(1,3-dithiol-2-ylidene)-9,10-dihydroanthracene polymers consisting of an oligomeric or polymeric compound of the general formula I have been found.

  所解决的问题是提供可用于高储存容量、长寿命和稳定充放电平台的电荷储存元件的活性介质的新型聚合物，其制备复杂度低，并且在合成过程中可以对其物理化学性质进行广泛控制。已发现由一般式I的寡聚物或聚合物化合物组成的9,10-双(1,3-二硫代-2-亚甲基)-9,10-二氢蒽聚合物。
• Novel Adenine Compound
  申请人：Hashimoto Kazuki

  公开号：US20080269240A1

  公开（公告）日：2008-10-30

  An adenine compound useful as a medicine represented by the following formula (1): [wherein R 1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A 1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A 2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L 1 and L 2 are independently, substituted straight or branched alkylene or a single bond, etc.; L 3 is optionally substituted straight or branched alkylene, etc.; R 2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.

  以下式子（1）所表示的一种腺嘌呤化合物，可用作药物：[其中，R1是卤素原子、可选取代烷基、可选取代芳基等；X是氧原子、硫原子、单键等；A1是可选取代和可饱和的4至8元杂环基，包含1至2个从1至3个氮原子、0至1个氧原子和0至1个硫原子中选取的杂原子；A2是可选取代的6至10环芳烃基或可选取代的5至10元杂环芳烃基；L1和L2是独立的、取代的直链或支链烷基或单键等；L3是可选取代的直链或支链烷基等；R2是氢原子、可选取代烷基等。]或其药学上可接受的盐。
• NOVEL ADENINE COMPOUND
  申请人：Millichip Ian

  公开号：US20090099216A1

  公开（公告）日：2009-04-16

  A novel adenine compound represented by the formula (1): wherein Z represents (un)substituted alkylene, a single bond, etc.; R 1 represents an (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl group; R 2 represents hydrogen or (un)substituted alkyl; R 3 , R 4 and R 5 each independently represents an (un)substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl group, provided that R 3 and R 5 may be bonded to each other to form a 3- to 7-membered, saturated carbocycle or heterocycle in cooperation with the adjacent carbon atom; and X represents oxygen, sulfur, SO 2 , NR 6 (R 6 represents hydrogen or alkyl), or a single bond, or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.

  一种新型腺嘌呤化合物，由公式（1）表示：其中Z代表（未）取代的烷基，单键等；R1代表（未）取代的烷基，烯基，炔基，环烷基，芳基或杂环芳基；R2代表氢或（未）取代的烷基；R3、R4和R5各自独立地表示（未）取代的烷基，烯基，炔基，芳基或杂环芳基，但R3和R5可以与相邻的碳原子合作形成3-至7-环的饱和碳环或杂环；X代表氧，硫，SO2，NR6（R6代表氢或烷基）或单键，或化合物的药学上可接受的盐。该化合物和盐可用作药物。
• QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：KOGA Yuji

  公开号：US20120136025A1

  公开（公告）日：2012-05-31

  Disclosed are quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R 0 )C(O)-lower alkylene-CO 2 R 0 , lower alkylene-CO 2 R 0 , lower alkenylene-CO 2 R 0 , —O-lower alkylene-CO 2 R 0 , —O-(lower alkylene which may be substituted with —CO 2 R 0 )-aryl or —O-lower alkenylene-CO 2 R 0 (wherein R 0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. The quinolone derivatives have excellent platelet aggregation inhibitory activity. A method of using the compounds is also disclosed.

  本发明涉及喹诺酮衍生物，其特征在于它们在1-位具有较低烷基、环烷基或类似物；在3-位具有-N(R0)C(O)-较低烷基烯基-CO2R0、较低烷基-CO2R0、较低烯基-CO2R0、-O-较低烷基-CO2R0、-O-（可能被取代为-CO2R0的较低烷基）芳基或-O-较低烯基-CO2R0（其中R0为H或较低烷基）；在6-位具有卤素；在7-位具有被环状取代基取代的氨基，或其药学上可接受的盐，具有出色的P2Y12抑制活性。这些喹诺酮衍生物具有优异的血小板聚集抑制活性。本发明还公开了一种使用这些化合物的方法。
• Method for producing cyclopentadienes
  申请人：NIPPON PETROCHEMICALS CO., LTD.

  公开号：EP0705812A1

  公开（公告）日：1996-04-10

  A method for producing cyclopentadienes which comprises the step of cyclodehydration of an unsaturated carbonyl compound having a specific chemical structures in a vapor phase in the presence of a specific solid acid catalyst. The cyclopentadienes of the invention can be produced in a high yield from inexpensive starting materials through a simplified reaction process and are useful as intermediate compounds for organic synthesis.

  一种生产环戊二烯的方法，包括在特定固体酸催化剂存在下，在气相中对具有特定化学结构的不饱和羰基化合物进行环脱水反应的步骤。本发明的环戊二烯可以用廉价的起始原料，通过简化的反应过程，以较高的产率生产出来，可用作有机合成的中间化合物。